CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 102 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,688,348 | -27.5% | 180,305 | -46.8% | 1.24% | -26.7% |
| Q2 2023 | $3,710,320 | +22.3% | 338,842 | -2.6% | 1.70% | -31.3% |
| Q1 2023 | $3,032,694 | +22.3% | 347,786 | -12.0% | 2.47% | +67.9% |
| Q4 2022 | $2,478,732 | +79.1% | 395,332 | 0.0% | 1.47% | +86.2% |
| Q3 2022 | $1,384,000 | +18.7% | 395,332 | 0.0% | 0.79% | +12.2% |
| Q2 2022 | $1,166,000 | +80.8% | 395,332 | +90.7% | 0.70% | +71.7% |
| Q1 2022 | $645,000 | -3.6% | 207,307 | +77.9% | 0.41% | -4.0% |
| Q4 2020 | $669,000 | – | 116,519 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |